Cipla, which is the third largest drug maker of the country has acquired the rights to market Percos India’s skincare products.

This deal will boost Cipla’s cosmetology portfolio that has been growing in recent years.

The deal size estimation is Rs 90 crore. Moreover, Cipla will now be holding the rights for marketing skincare products of Percos India that are estimated at a collective sale value of Rs 10 crore.

Percos India will manufacture the skincare brands for the next five years post to that Cipla will get the rights to manufacture them as well.

Read stocks to buy today